Skip to main content
. 2013 Nov 18;8(11):e80639. doi: 10.1371/journal.pone.0080639

Table 2. Results of the baseline cost-effectiveness analysis.

Name of the Strategy Costs (US dollars) Effectiveness (DALYS) Average C-E Ratio¥ Incremental Costs Incremental Effectiveness(Averted DALYS) Incremental C-E Ratio ∞
No Vaccination 551 3.483 158
Quadrivalent Vaccine 688 3.478 198 137 0.00563 24241
Bivalent vaccine 713 3.478 205 162 0.00563 28765

¥ Strategy costs divided by DALYS

∞ Strategy Costs - ‘No vaccination’ Costs / ‘No vaccination’ DALYS - Strategy DALYS